Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 10/26 10:01:40 am
442.95 DKK   -0.52%
08:48aNOVO NORDISK A/S : – Share repurchase programme
AQ
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/14NOVO NORDISK : Buy rating from JP Morgan
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
451(c) 446.35(c) 444.1(c) 445.25(c) 443.15 Last
1 793 081 2 380 102 2 474 490 1 558 012 730 637 Volume
-0.03% -1.03% -0.50% +0.26% -0.47% Change
More quotes
Financials
Sales 2020 128 B 20 316 M 20 316 M
Net income 2020 42 262 M 6 716 M 6 716 M
Net cash position 2020 10 720 M 1 703 M 1 703 M
P/E ratio 2020 24,7x
Yield 2020 2,03%
Sales 2021 136 B 21 589 M 21 589 M
Net income 2021 45 585 M 7 244 M 7 244 M
Net cash position 2021 14 977 M 2 380 M 2 380 M
P/E ratio 2021 22,3x
Yield 2021 2,19%
Capitalization 1 035 B 165 B 164 B
EV / Sales 2020 8,01x
EV / Sales 2021 7,51x
Nbr of Employees 43 526
Free-Float 75,1%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
10/30Earnings Release
More about the company
Notations Surperformance© of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
All news about NOVO NORDISK A/S
08:48aNOVO NORDISK A/S : – Share repurchase programme
AQ
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/14NOVO NORDISK : Buy rating from JP Morgan
MD
10/12NOVO NORDISK : Credit Suisse gives a Buy rating
MD
10/12NOVO NORDISK A/S : Bavarian Nordic Announces Appointment of Anu Helena Kerns as ..
AQ
10/12NOVO NORDISK A/S : Conference call regarding updated 2020 outlook 9 October 2020
PU
10/12NOVO NORDISK A/S : Alexander Mann Solutions partners with Novo Nordisk to suppor..
AQ
10/12NOVO NORDISK A/S : – Share repurchase programme
AQ
10/09EUROPE : European stocks rack up second week of gains, Pandora leaps
RE
10/09NOVO NORDISK : Credit Suisse gives a Buy rating
MD
10/09GLOBAL MARKETS LIVE : Acquisitions, acquisitions, acquisitions
10/09Sobi shares fall 17% as Avatrombopag study fails to meet primary endpoint
RE
10/09NOVO NORDISK : UBS sticks Neutral
MD
10/09NOVO NORDISK : DZ Bank reiterates its Sell rating
MD
10/09NOVO NORDISK : Sell rating from Jefferies
MD
More news
News in other languages on NOVO NORDISK A/S
10/16NOVO NORDISK : Goldman Sachs toujours positif
10/16Goldman belässt Novo Nordisk auf 'Conviction Buy List'
10/14NOVO NORDISK : JP Morgan maintient sa recommandation à l'achat
10/14JPMorgan belässt Novo Nordisk auf 'Overweight' - Ziel 480 Kronen
10/12NOVO NORDISK : Credit Suisse toujours positif
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 447,63 DKK
Last Close Price 445,25 DKK
Spread / Highest target 22,4%
Spread / Average Target 0,53%
Spread / Lowest Target -31,5%
EPS Revisions
Managers
NameTitle
Lars Fruergaard JÝrgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S15.16%164 690
JOHNSON & JOHNSON-0.43%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999